Elizabeth Yonko

Elizabeth Yonko

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2020 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
SKSobiah I. Mbs Khan
Sobiah I. Mbs Khan
EYElizabeth Yonko
Elizabeth Yonko
ECErin M. Ms Carter
Erin M. Ms Carter
DDDebra Dyer
Debra Dyer
RSRobert A. Sandhaus
Robert A. Sandhaus
CRCathy L. Raggio
Cathy L. Raggio
Background: Osteogenesis imperfecta (OI) is a heterogeneous group of collagen-related disorders characterized by osteopenia, bone fractures, spine deformities, and nonskeletal complications. Cardiopulmonary complications are the major cause of morbidity and mortality in adults with OI. The cause of such problems was often attributed solely to the presence of large scoliosis curves affecting pulmonary function and, indirectly, cardiovascular health. However, recent studies suggest this may not be the case. Therefore, determining the relationships and causative agents of cardiopulmonary problems in patients with OI, specifically pulmonary impairment, is important to improving the overall wellbeing, quality of life, and survival of these patients. Questions/purposes: (1) Is cardiopulmonary fitness in OI solely related to the presence of scoliosis? (2) What is the prevalence of heart and lung complications in this adult population? (3) Does the presence of pulmonary impairment impact quality of life in adults with OI? Methods: This is a prospective observational cross-sectional study. Within 1 year, each participant (n = 30) completed pulmonary function testing, echocardiogram, ECG, chest CT, AP spine radiography, and quality-of-life assessments (SF-36, St. George’s Respiratory Questionnaire, Functional Outcomes of Sleep Questionnaire, and Pittsburgh Sleep Quality Index). In terms of pulmonary function, we differentiated restrictive and obstructive physiology using the ratio of forced expiratory volume over one second to forced vital capacity (FEV1/FVC), with restrictive lung physiology defined as FEV1/FVC > 0.8 and obstructive lung physiology as FEV1/FVC < 0.7. Spine radiographs were evaluated for scoliosis. Chest CT images were reviewed to qualitatively assess the lungs. The statistical analysis involved a Kruskall-Wallis test with Bonferroni’s correction and a bivariate correlation analysis using Spearman’s rho correlation coefficient (p < 0.05). Results: Sixteen of 23 participants with restrictive lung physiology had scoliosis; their ages ranged from 19 years to 67 years. There was no correlation between the magnitude of the scoliosis curve and deficient pulmonary function (R = 0.08; p = 0.68). Seven participants had normal pulmonary function. The average scoliosis curve was 44 ± 29°. Thirteen participants had abnormal ECG findings while 10 had abnormal echocardiogram results. All but two individuals with abnormal chest CT results were found to have bronchial wall thickening. There were no differences in pulmonary or cardiac findings between OI types, except for FVC and total lung capacity, which were lower in individuals with Type III OI than in those with other types of OI. FEV1/FVC correlated with St. George’s Respiratory Questionnaire (R = 0.429; p = 0.02) but not with Functional Outcomes of Sleep Questionnaire (R = -0.26; p = 0.19) or SF-36 scores (physical component summary: R = -0.037, p = 0.85; mental component summary: R = -0.204, p = 0.29). Conclusions: The lack of a relationship between decreased pulmonary function and the severity of scoliosis suggests that restrictive lung physiology in this population is likely because of factors intrinsic to OI and not entirely because of thoracic cage deformities. The fact that pulmonary impairment influences self-perceived quality of life exemplifies how detrimental such complications may be to everyday functioning. This also reinforces the importance of determining the underlying cause of cardiopulmonary impairment in this population to set clear clinical guidelines of care. Level of Evidence: Level II, prognostic study.

29 November 2021 in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
Verified
Journal Article
Closed access
PDF file
EYElizabeth Yonko
Elizabeth Yonko
HLHolly M. LoTurco
Holly M. LoTurco
ECErin M. Carter
Erin M. Carter
CRCathy L. Raggio
Cathy L. Raggio

24 December 2020 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
EYElizabeth Yonko
Elizabeth Yonko
JEJillian S. Emanuel
Jillian S. Emanuel
ECErin M. Carter
Erin M. Carter
CRCathy L. Raggio
Cathy L. Raggio

1 August 2020 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
CRCathleen L. Raggio
Cathleen L. Raggio
EYElizabeth Yonko
Elizabeth Yonko
SKSobiah I. Khan
Sobiah I. Khan
ECErin M. Carter
Erin M. Carter
KCKate P. Citron
Kate P. Citron
MFMark P. Figgie
Mark P. Figgie

19 January 2020 in Journal of Biophotonics
Verified
Journal Article
Closed access
PDF file
NSNo'Ad Shanas
No'Ad Shanas
WQWilliam Querido
William Querido
ADAlexander Dumont
Alexander Dumont
EYElizabeth Yonko
Elizabeth Yonko
ECErin Carter
Erin Carter
NPNancy Pleshko
Nancy Pleshko

1 March 2025 in AIDS Patient Care and STDs
Verified
Journal Article
Closed access
EYElizabeth Yonko
Elizabeth Yonko
KBKatie B. Biello
Katie B. Biello
COCarolina Cormack Orellana
Carolina Cormack Orellana
OROlly Richards
Olly Richards
CWConnor Wright
Connor Wright
MMMatthew J. Mimiaga
Matthew J. Mimiaga
Bacterial sexually transmitted diseases (STDs) remain prominent in the United States among gay, bisexual, and other men who have sex with men (GBMSM). Doxycycline for post-exposure prophylaxis (DoxyPEP) is a regimen by which the antibiotic doxycycline is taken after sex to prevent bacterial STDs, such as, chlamydia, gonorrhea, and syphilis. Despite this, this study was conducted because there are a limited number of publications that describe GBMSM's knowledge of, and interest in, taking DoxyPEP and preferences regarding its implementation. We conducted a mixed-methods study between November 2023 and March 2024. Participants (N = 21) completed a semi-structured interview and survey and were eligible if they were a cisgender man who reported having anal sex with another man in the past year and lived in the greater Los Angeles area. Interviews were recorded and transcribed and were analyzed using thematic content analysis. The majority of participants identified as gay (90%) and a racial/ethnic minority (86%); 33% were living with HIV and 43% had been diagnosed with an STD in the prior year. Participants' mean age was 40 years (standard deviation [SD] = 15) and they reported an average of 4.5 (SD = 2.27) sexual partners in the past year. Interviews revealed that knowledge of DoxyPEP was low (28%), but most (81%) were interested in using DoxyPEP after learning about its potential. The vast majority were willing to pay $10-$20 for a 1-month supply but preferred that it be free or covered by insurance. Most preferred to get DoxyPEP from a medical provider or over-the-counter at a pharmacy. Others suggested sexualized venues, such as private sex parties, bathhouses, sex clubs, etc. The greatest concerns about its use included possible side effects, antibiotic resistance, or that it would lead to decreased condom use and increased number of sex partners. A common misconception was that DoxyPEP could prevent both a bacterial STD and HIV. DoxyPEP has strong potential as a widely accepted STD prevention method, but its successful adoption will require proactive strategies to increase GBMSM's knowledge. Implementation programs might consider nontraditional venues where sex between men is regularly occurring.